Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model

European Journal of Cancer

Volumn 45, Issue 13, 2009, Pages 2391-2401

  Charasson, Virginie ^a,b   Hillaire Buys, Dominique ^a   Solassol, Isabelle ^b   Laurand Quancard, Armelle ^c,d,e   Pinguet, Frédéric ^b   Morvan, Valérie Le ^c,d,e   Robert, Jacques ^c,d,e  

^a LAPEYRONIE HOSPITAL   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT BERGONIÉ   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e INSERM   (France)

Author keywords

Chemotherapy; Drug cytotoxicity; Folate pathway; Gene polymorphisms; Methionine synthase; Methotrexate; Methylene tetrahydrofolate dehydrogenase; Methylene tetrahydrofolate reductase; NCI 60 panel; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; ALKYLATING AGENT; ANTIMETABOLITE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; FOLIC ACID; FOLIC ACID ANTAGONIST; MELPHALAN; METHIONINE SYNTHASE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; NITROSOUREA; PLATINUM COMPLEX; RALTITREXED; REDUCED FOLATE CARRIER; TAXANE DERIVATIVE;

ALLELE; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SENSITIVITY; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HUMAN; HUMAN CELL; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL LINE;

EID: 68749104523     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.013     Document Type: Article

References (51)

1. Calvert H. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol 26 Suppl 6 (1999) 3-10
2. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metastasis Rev 26 (2007) 153-181
3. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
4. van der Put N.M., Gabreëls F., Stevens E.M., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Human Genet 62 (1998) 1044-1051
5. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
6. Chen J., Ma J., Stampfer M.J., et al. Linkage disequilibrium between the 677C>T and 1298A>C polymorphisms in human methylenetetrahydrofolate reductase gene and their contributions to risk of colorectal cancer. Pharmacogenetics 12 (2002) 339-342
7. Pereira T.V., Rudnicki M., Pereira A.C., Pombo-de-Oliveira M.S., and Franco R.F. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15 (2006) 1956-1963
8. Lissowska J., Gaudet M.M., Brinton L.A., et al. Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: a population-based case-control study and meta-analyses. Int J Cancer 120 (2007) 2696-2703
9. Huang Y., Han S., Li Y., Mao Y., and Xie Y. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Human Genet 52 (2007) 73-85
10. Boccia S., Hung R., Ricciardi G., et al. Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. Am J Epidemiol 167 (2008) 505-516
11. Robert J., Le Morvan V., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54 (2005) 171-196
12. Toffoli G., and Cecchin E. Uridine diphosphoglucuronosyl transferase and methylene-tetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy. J Chemother 16 Suppl 4 (2004) 31-35
13. Abraham J., Earl H.M., Pharoah P.D., and Caldas C. Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta 1766 (2006) 168-183
14. Leclerc D., Campeau E., Goyette P., et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Human Mol Genet 5 (1996) 1867-1874
15. Ulrich C.M., Curtin K., Potter J.D., Bigler J., Caan B., and Slattery M.L. Polymorphisms in the reduced folate carrier, thymidylate synthase, or methionine synthase and risk of colon cancer. Cancer Epidemiol Biomark Prev 14 (2005) 2509-2516
16. Shi Q., Zhang Z., Li G., et al. Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. Pharmacogenet Genomics 15 (2005) 547-555
17. Stevens V.L., McCullough M.L., Pavluck A.L., et al. Association of polymorphisms in one-carbon metabolism genes and postmenopausal breast cancer incidence. Cancer Epidemiol Biomark Prev 16 (2007) 1140-1147
18. Krajinovic M., Lemieux-Blanchard E., Chiasson S., et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenom J 4 (2004) 66-72
19. Chango A., Emery-Fillon N., de Courcy G.P., et al. A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70 (2000) 310-315
20. Laverdière C., Chiasson S., Costea I., Moghrabi A., and Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100 (2002) 3832-3834
21. Monks A., Scudiero D., Skehan P., et al. Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83 (1991) 757-766
22. Le Morvan V., Bellott R., Moisan F., et al. Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel. Pharmacogenomics 7 (2006) 843-852
23. Yarosh D.B., Peña A., and Brown D.A. DNA repair gene polymorphisms affect cytotoxicity in the National Cancer Institute Human Tumour Cell Line Screening Panel. Biomarkers 10 (2005) 188-202
24. Moisan F., Longy M., Robert J., and Le Morvan V. Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines. Brit J Cancer 95 (2006) 906-913
25. Nief N., Le Morvan V., and Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur J Cancer 43 (2007) 955-962
26. Scherf U., Ross D.T., Waltham M., et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 24 (2000) 236-244
27. Kurzawski M., Pawlik A., Safranow K., Herczynska M., and Drozdzik M. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 8 (2007) 1551-1559
28. Wessels J.A., de Vries-Bouwstra J.K., Heijmans B.T., et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 54 (2006) 1087-1095
29. Hughes L.B., Beasley T.M., Patel H., et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1213-1218
30. Bohanec Grabar P., Logar D., Lestan B., and Dolžan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. Eur J Clin Pharmacol 64 (2008) 1057-1068
31. Chiusolo P., Reddiconto G., Casorelli I., et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13 (2002) 1915-1918
32. Toffoli G., Veronesi A., Boiocchi M., and Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 11 (2000) 373-374
33. Toffoli G., Russo A., Innocenti F., et al. Effect of methylene-tetrahydrofolate reductase 677C>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103 (2003) 294-299
34. Aplenc R., Thompson J., Han P., et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65 (2005) 2482-2487
35. de Jonge R., Hooijberg J.H., van Zelst B.D., et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106 (2005) 717-720
36. Cohen V., Panet-Raymond V., Sabbaghian N., et al. Methylene-tetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9 (2003) 1611-1615
37. Etienne M.C., Formento J.L., Chazal M., et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14 (2004) 785-792
38. Jakobsen A., Nielsen J.N., Gyldenkerne N., and Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23 (2005) 1365-1369
39. Wu X., Gu J., Wu T.T., et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24 (2006) 3789-3798
40. Sharma R., Hoskins J.M., Rivory L.P., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 14 (2008) 817-825
41. Marcuello E., Altés A., Menoyo A., Rio E.D., and Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?. Cancer Chemother Pharmacol 57 (2006) 835-840
42. Sohn K.J., Croxford R., Yates Z., Lucock M., and Kim Y.I. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96 (2004) 134-144
43. Etienne M.C., Ilc K., Formento J.L., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Brit J Cancer 90 (2004) 526-534
44. Stevenson J.P., Redlinger M., Kluijtmans L.A., et al. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 19 (2001) 4081-4087
45. Dong L.M., Potter J.D., White E., et al. Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299 (2008) 2423-2436
46. Choi S.W., and Mason J.B. Folate status: effects on pathways of colorectal carcinogenesis. J Nutr 132 (2002) 2413S-2418S
47. Larsson S.C., Giovannucci E., and Wolk A. Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 131 (2006) 1271-1283
48. Krajinovic M., Lamothe S., Labuda D., et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103 (2004) 252-257
49. Roje S., Chan S.Y., Kaplan F., et al. Metabolic engineering in yeast demonstrates that S-adenosylmethionine controls flux through the methylenetetrahydrofolate reductase reaction in vivo. J Biol Chem 277 (2002) 4056-4061
50. Wiemels J.L., Smith R.N., Taylor G.M., et al. Methylene-tetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci USA 98 (2001) 4004-4009
51. Krajinovic M. MTHFD1 gene: role in disease susceptibility and pharmacogenetics. Pharmacogenomics 9 (2008) 829-832